Eledon Pharmaceuticals/$ELDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eledon Pharmaceuticals
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Ticker
$ELDN
Sector
Primary listing
Employees
33
Headquarters
Website
ELDN Metrics
BasicAdvanced
$234M
-
-$0.56
0.96
-
Price and volume
Market cap
$234M
Beta
0.96
52-week high
$4.60
52-week low
$1.35
Average daily volume
1.4M
Financial strength
Current ratio
7.397
Quick ratio
7.297
Long term debt to equity
0.207
Total debt to equity
0.469
Profitability
Effective tax rate (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-30.04%
Return on equity (TTM)
-35.79%
Valuation
Price to book
1.7
Price to tangible book (TTM)
2.23
Price to free cash flow (TTM)
-4.049
Free cash flow yield (TTM)
-24.70%
Free cash flow per share (TTM)
-0.761
Growth
Earnings per share change (TTM)
-25.15%
3-year earnings per share growth (CAGR)
-55.12%
10-year earnings per share growth (CAGR)
-30.25%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eledon Pharmaceuticals stock?
Eledon Pharmaceuticals (ELDN) has a market cap of $234M as of April 01, 2026.
What is the P/E ratio for Eledon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eledon Pharmaceuticals (ELDN) stock is 0 as of April 01, 2026.
Does Eledon Pharmaceuticals stock pay dividends?
No, Eledon Pharmaceuticals (ELDN) stock does not pay dividends to its shareholders as of April 01, 2026.
When is the next Eledon Pharmaceuticals dividend payment date?
Eledon Pharmaceuticals (ELDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eledon Pharmaceuticals?
Eledon Pharmaceuticals (ELDN) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.